Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 12

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 12
---
2025, we entered into a securities purchase agreement with investors for the purchase and sale of (i) 7,944,868 common shares, and (ii) pre-funded warrants to purchase up to 2,865,960 common shares, in a registered direct offering, or the Fourth November 2025 Offering, at a purchase price of $0.12 per common share and $0.1199 per pre-funded warrant. The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full. The Fourth November 2025 Offering closed November 26, 2025. The aggregate gross proceeds to the Company were approximately $1.294 million. December 2025 Registered Direct Offering On December 3, 2025, we entered into a securities purchase agreement with investors for the purchase and sale of 16,000,000 common shares, in a registered direct offering, or the December 2025 Offering, at a purchase price of $0.10 per common share. The December 2025 Offering closed December 4, 2025. The aggregate gross proceeds to the Company were approximately $1.6 million. Warrant Exercises As of the date hereof, investors from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants to purchase 1,881,250 common shares on a cashless basis. As a result, we issued an aggregate of 2,090,987 common shares and received aggregate gross proceeds of approximately $183,000 from such exercises. Convertible Notes Securities Purchase Agreement On September 17, 2025, we entered into the SPAs with the CLA Investors. The SPAs provide that, upon the terms and subject to the conditions set forth therein, we shall issue and sell to the CLA Investors, as provided therein, Promissory Notes for the Subscription Amount, which may be convertible into our common shares, in the aggregate principal amount of $2.5 million, for an aggregate purchase price of $2.25 million (90% of the Subscription Amount). Upon the signing of the SPAs on September 17, 2025, or the First Initial Closing, the CLA Investors purchased from us Promissory Notes in the aggregate principal amount of $555,556, for a purchase price of $500,000. Subject to the